ACM
RCKT icon

AlphaCrest Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

AlphaCrest Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,199
Closed -$498K – 894
2022
Q3 		$498K Buy
+31,199
New +$487K 0.03% 982

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCrest Capital Management's RCKT Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q4 2022, closing a stake of 31,199 shares — an estimated $498K sold.

AlphaCrest Capital Management first reported a position in RCKT in Q3 2022 and held it in 1 quarter. The position peaked at $498K in Q3 2022. 168 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Rocket Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 31,199 Rocket Pharmaceuticals shares in Q4 2022, an estimated $498K.
  • AlphaCrest Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • AlphaCrest Capital Management's Rocket Pharmaceuticals position peaked at $498K in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.